Drug Research
AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to develop and commercialise NI006
Alexion, AstraZeneca’s Rare Disease group, has entered into an exclusive global collaboration and licence agreement with Neurimmune AG for NI006, an investigational human monoclonal antibody currently in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). NI006...
Drug Research
In-Vitro Biology Capabilities Expanded By Piramal Pharma
Piramal Pharma Solutions has confirmed that it has put in a multi-million dollar investment to create a top-notch screening facility that will elevate the in-vitro biology capabilities of its drug discovery service site at Ahmedabad in India.
The new expansion...
Drug Research
Ascletis expands production of ritonavir oral tablets & oral direct-acting antiviral R&D pipeline to treat SARS-CoV-2 infection
Ascletis Pharma Inc. announces the expansion of the production of ritonavir oral tablets and oral direct-acting antiviral R&D pipeline for the treatment of SARS-CoV-2 infection. The company’s Covid-19 pipeline currently includes (i) ritonavir oral tablet (100 mg), an authorized...
Drug Research
Amyris and Immunitybio Complete Joint Venture for Next Generation Covid-19 RNA Vaccine
Amyris, Inc., a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-Market operating platform, and ImmunityBio, a clinical-stage immunotherapy company, today announced the completion of a previously announced joint venture agreement to accelerate the commercialization...
Drug Research
REGENXBIO Announces Orphan Drug Designation Granted to RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy
REGENXBIO Inc. announced the U.S. FDA granted Orphan Drug Designation for RGX-202, a potential one-time gene therapy for the treatment of Duchenne muscular dystrophy (Duchenne). RGX-202 is designed to deliver a novel, optimized microdystrophin transgene with a unique C-terminal...
Drug Research
Chiesi Group focuses on biological drugs: an investment of 85 million euros for an international centre of excellence in Parma
Chiesi, the international research-focused pharmaceuticals and healthcare Group (Chiesi Group), presented today to the Italian Minister of Economic Development Giancarlo Giorgetti in Rome, the Biotech Center of Excellence Plant project, the new hub for the development of biological products....
Drug Research
ViiV Healthcare announces US FDA approval of Apretude, the first and only long-acting injectable option for HIV prevention
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (Pfizer) and Shionogi Limited (Shionogi) as shareholders, announced that the US Food and Drug Administration (FDA) approved Apretude, the first and only long-acting...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.